Tuesday, 22 Sep 2026
Empowering Chinese Pharma’s Global Expansion
Contact US
Home
About US
Policy Hub
Categories
Drug
Company
Deals
Policy / Regulatory
Medical Device
R&D
Legal / IP
Digital
Privacy Policy
Contact US
My News
Cancer
Clinical trial approval / initiation
Product approvals
Clinical trial results
Finance
ADC / XDC
Finanical Reports
Biotech
Market approval filings
PD-1/L1
Read History
Search
Pages
Home
Blog Index
POLICY HUB
Contact Us
Personalized
Read History
Categories
Company
Drug
Policy / Regulatory
Medical Device
R&D
Digital
Legal / IP
Deals
Have an existing account?
Sign In
Follow US
Fineline Cube
Follow:
14467
Articles
Company
Viatris Reports 8% Revenue Growth in Q1 2026 Fueled by Greater China Surge and Brand Portfolio Strength
May 8, 2026
Company
Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion
May 8, 2026
Company
Deals
Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation
May 8, 2026
Company
Drug
Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment
May 8, 2026
Company
Drug
Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential
May 8, 2026
Company
Drug
Suzhou Zelgen Biopharmaceuticals Achieves Primary Endpoint in Phase III Trial for Zesuning in Thyroid Cancer Ablation Therapy
May 8, 2026
Company
Drug
Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment
May 8, 2026
Legal / IP
Policy / Regulatory
China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight
May 8, 2026
Policy / Regulatory
China’s NHC Unveils 16-Point Pediatric Medicines Reform to Strengthen Supply Security and Clinical Access
May 8, 2026
Company
Deals
Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist
May 7, 2026
Company
GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook
May 7, 2026
Company
Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%
May 7, 2026
1
2
…
103
104
105
106
107
…
1,205
1,206
Welcome to Fineline Cube!
Username or Email Address
Password
Remember me
Lost your password?